People who are infected should also take vaccine: Bharat Biotech Chairman

People who are infected should also take a vaccine,and India is well prepared regarding the logistics for the vaccine distribution,Bharat BiotechChairman & MD Krishna Ella said on Wednesday.

People who are infected should also take vaccine: Bharat Biotech Chairman
Press Trust of India New Delhi
2 min read Last Updated : Dec 23 2020 | 7:27 PM IST

People who are infected should also take a vaccine,and India is well prepared regarding the logistics for the vaccine distribution,Bharat BiotechChairman & MD Krishna Ella said on Wednesday.

He was speaking in a virtual session on 'Sero surveillance significance in immunogenicity and safety in pre and post vaccination era' organised by industrybody CII.

For the peoplewho are infected,shouldthey take a vaccine, "the answeris yes", becausethey may not have a goodT cells response..., Ella said.

Talking about the company's efficacy trials of its COVID-19 vaccine, he said that for the efficacy trials the company has taken 24 centres all over the country so that it has tier I ,tierIIand tier III cities to capture the efficacy in a better way.

On the distribution of vaccines in India, he said India is well prepared for that and Indian immunisation system is very robust, Ella said.

Speaking at the session, Biocon ChairpersonKiran Mazumdar Shaw said, "We have to ensure we have a sense of pandemic preparedness moving ahead".

"We need to understand the need for a concerted effort and a very importantparadigm which is based on both antigen and antibody testing is going to be of an immense importancegoing forward," she added.

About the roadmap, Mazumdar Shaw said: "If we can come up with algorithms and paradigms, which many universities in other parts of the world are looking at as a COVID calculator, we can alsocome up with very interestingparadigms that will tell us which parts of our society and communities are safe and which parts of our community has actually developed herd immunities and which parts of our country can be opened up with ease".

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineBharat BiotechVaccination

First Published: Dec 23 2020 | 7:23 PM IST

Next Story